NCT02320305View on ClinicalTrials.gov

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

December 7, 2015

Study Completion Date

April 11, 2019

Conditions
Stage IIA Skin MelanomaStage IIB Skin MelanomaStage IIC Skin MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma
Interventions
BIOLOGICAL

MART-1 Antigen

Given IM

DRUG

TLR4 Agonist GLA-SE

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER